On March 17, 2018, the three-day 15th China (International) Laboratory Medicine and Blood Transfusion Instrument and Reagent Expo (CACLP) officially kicked off at the Chongqing International Expo. As the most important and most concentrated exhibition of laboratory medical instruments and reagents in the domestic in vitro diagnostic field, it attracted nearly 800 manufacturers at home and abroad, and more than 30,000 people participated in this feast of the in vitro diagnostic industry.
Picture 1.png
Although it was the first appearance of CACLP, Ao Cheng and his team did not participate as a single observer, but took part in the conference with three independently designed and developed platforms and solutions. The three platforms exhibited during the exhibition attracted much attention.
1. i-Sort microfluidic immunofluorescence quantitative detection platform
The i-Sort microfluidic immunofluorescence quantitative detection platform integrates leading microfluidic detection technology with independent intellectual property rights and advanced immunofluorescence quantitative detection technology, which can perform one-step detection of serum, plasma, whole blood and other test samples Quick diagnosis and precise quantification. As a new generation of POCT detection system, i-Sort not only has ultra-high detection sensitivity, but also has excellent performance in detection repeatability. In conjunction with the self-developed special microfluidic test card, i-Sort can help more quickly solve the diagnosis in areas such as maternal and child health, infection and inflammation, and cardiovascular and cerebrovascular diseases.
Instrument plus chip.jpg
2. iRaTe fluorescence immunoassay platform
The iRaTe fluorescence immunoassay platform is equipped with Aocheng related diagnostic reagents. According to different throughputs, different instruments (iRaTe 300/iRaTe 1600) can be selected to meet the needs of different customers. It has the characteristics of stable performance, simple operation, high sensitivity, and high accuracy. , The monitoring scope can simultaneously cover many fields such as maternal and child health, bone calcium metabolism, anemia ischemia, infection and inflammation, cardiovascular and cerebrovascular.
4.png
IRaTe-Effect Picture 2 Original.png
3. iMAGIN chemiluminescence immunoassay platform
The iMAGIN chemiluminescence immunoassay platform uses the international mainstream chemiluminescence technology platform-acridinium ester direct luminescence method, which enables rapid concentration of luminescence, higher efficiency, and the test speed can reach 180T/h; because the luminescent substance directly labels the antigen or antibody, the accuracy is achieved Better; the molecular weight of the marker is small, which reduces the steric hindrance, making the antigen-antibody reaction better, and the sensitivity is higher; the marker is not affected by the oxidant in the environment, and the stability is better.
5-26.2186.png
About Aocheng
Ningbo Aocheng Biotechnology Co., Ltd. is a high-tech biological enterprise focusing on the early detection, diagnosis, prevention and monitoring of diseases. By providing reliable, fast and convenient in vitro diagnostic products, it can provide accurate test results for diagnosis and treatment. At present, the company's biomedical team continues to conduct in-depth exploration and prospective research in the field of high-risk diseases for pregnant women such as hypertension. We will be committed to providing leading clinical diagnosis solutions for maternal and child health.
The Aocheng R&D team brings together global technical forces, integrates the best talents at home and abroad, and builds a technology platform based on microfluidic technology, immunofluorescence, chemiluminescence, molecular diagnosis, and antibody raw material research and development. A series of products developed in subjects such as diabetes, infection, kidney disease, and oncology. In the future, we will mainly use advanced technologies such as artificial intelligence and medical big data to add value to the current diagnostic platform, and create value for medical institutions and patients.
